公司点评 · 家用电器行业 商业航天影子龙头，控股乾照光电 2026 年 01 月 11 日 核心观点 | 主要财务指标预测 | | | | | | --- | --- | --- | --- | --- | | | 2024A | 2025E | 2026E | 2027E | | 营业收入(百万元) | 58,530 | 61,641 | 69,213 | 75,926 | | 收入增长率% | 9.17 | 5.31 | 12.28 | 9.70 | | 归母净利润(百万元) | 2,246 | 2,677 | 2,997 | 3,413 | | 利润增长率% | 7.17 | 19.20 | 11.93 | 13.88 | | 摊薄 EPS(元) | 1.72 | 2.05 | 2.30 | 2.62 | | PE | 14.12 | 11.84 | 10.58 | 9.29 | 资料来源：公司公告，中国银河证券研究院（注：收盘价为 2026 年 1 月 9 日） 海信视像（股票代码：600060） 推荐 维持评级 分析师 何伟 ：hewei_yj@chinastock.com.cn 分析师登记编码： ...

Investment Rating - The report maintains a "Strong Buy" rating for the company [2][4]. Core Insights - The company is expected to see high levels of related transactions, with a forecasted related procurement amount of 21.637 billion, reflecting a slight decrease of 3.78% compared to the previous year, but still indicating sustained high demand [8]. - Anticipation for the official debut of the H-20 model in 2026 may provide new growth opportunities for the company [8]. - Revenue and profit are projected to grow steadily, with net profit estimates for 2025, 2026, and 2027 at 1.141 billion, 1.302 billion, and 1.488 billion respectively, corresponding to price-to-earnings ratios of 73, 64, and 56 [2][3]. Financial Data and Valuation - Total revenue is projected to increase from 40.301 billion in 2023 to 59.188 billion in 2027, with year-on-year growth rates of 7%, 7%, 5%, 13%, and 15% respectively [3][16]. - Operating profit is expected to rise from 1.023 billion in 2023 to 1.727 billion in 2027, with significant growth rates of 75%, 16%, 12%, 14%, and 14% [3][16]. - The company's net profit attributable to shareholders is forecasted to grow from 861 million in 2023 to 1.488 billion in 2027, with growth rates of 65%, 19%, 11%, 14%, and 14% [3][16]. - The company’s earnings per share (EPS) is projected to increase from 0.31 in 2023 to 0.54 in 2027 [3][16]. - The report indicates a current price-to-earnings (PE) ratio of 96.8 for 2023, decreasing to 56.0 by 2027 [3][16].

Investment Rating - The report assigns a "Buy" rating for Lingyun Co., Ltd. (600480) for the first time [1]. Core Views - Lingyun Co., Ltd. is a leading automotive parts manufacturer with a focus on expanding into liquid cooling and robotics sectors. The company has a robust growth trajectory with a projected revenue CAGR of 6% and a net profit CAGR of 39% from 2022 to 2024 [9]. - The company is well-positioned in the metal and plastic parts sector, benefiting from the ongoing electrification trend in the automotive industry, with significant growth expected in the battery box and liquid cooling markets [9]. - The report anticipates a steady increase in net profit, projecting it to reach 800.99 million yuan in 2025, 908.54 million yuan in 2026, and 1,054.65 million yuan in 2027, with corresponding year-on-year growth rates of 22.21%, 13.43%, and 16.08% respectively [1]. Summary by Sections Company Overview - Lingyun Co., Ltd. has been operating for over 30 years, focusing on automotive metal and plastic components, and has expanded into emerging fields such as thermal management and sensors. The company has a stable ownership structure, with significant control by the China Ordnance Industry Group [15][23]. Metal Segment - The metal segment is benefiting from the trend towards lightweight and electrification, with the hot-formed stamping parts expected to see increased demand. The domestic market for hot-formed parts is projected to exceed 200 billion yuan by 2024 [9][36]. - The company has established a competitive advantage through technological advancements and capacity expansion, particularly in the battery box sector, where it serves major clients like BMW and Porsche [9][56]. Automotive Pipeline Segment - The automotive pipeline segment is experiencing steady growth, driven by the increasing penetration of electric vehicles. The domestic market for automotive pipelines is expected to surpass 200 billion yuan by 2024 [9][30]. - The company has formed strategic partnerships to enhance its product offerings and has successfully entered new markets, including high-end oil service equipment and nuclear power sectors [9][30]. New Business Ventures - Lingyun Co., Ltd. is rapidly entering the liquid cooling market, which is projected to be worth hundreds of billions. The company has developed a product matrix that includes liquid cooling pipes and connectors, securing orders from data centers and supercomputing facilities [9][5]. - In the sensor field, the company is leading a project funded by the Ministry of Industry and Information Technology to develop six-dimensional force sensors, with several small batch orders already delivered [9][5]. Financial Projections - The report forecasts that the company's net profit will reach 800.99 million yuan in 2025, 908.54 million yuan in 2026, and 1,054.65 million yuan in 2027, with corresponding P/E ratios of 19, 17, and 14 respectively [1][9].

Investment Rating - The investment rating for the company is "Buy" [4] Core Insights - The coal machinery industry is experiencing a cyclical bottoming, with multiple drivers such as replacement, automation, and export opportunities expected to benefit the leading state-owned enterprises [1] - The company has a comprehensive industry chain layout, with notable performance in safety and automation [2] - The company reported a 7.5% year-on-year increase in net profit attributable to shareholders for the first three quarters of 2025, despite a 6.9% decline in revenue [2] - The company’s gross margin for the first three quarters of 2025 was 27.2%, down 5.2 percentage points year-on-year, while the net margin increased by 4.4 percentage points to 17.2% [3] Financial Performance Summary - For the first three quarters of 2025, the company achieved revenue of 20.47 billion yuan, a decrease of 6.9% year-on-year, and a net profit of 2.34 billion yuan, an increase of 7.5% year-on-year [2][10] - The company’s operating income for 2025 is projected to be 30.6 billion yuan, with a compound annual growth rate (CAGR) of 6% from 2025 to 2027 [4] - The net profit attributable to shareholders is expected to be 2.6 billion yuan in 2025, with a CAGR of 10% from 2025 to 2027 [4] - The company’s price-to-earnings (P/E) ratios are projected to be 9.3X, 8.6X, and 7.7X for 2025, 2026, and 2027, respectively [4] Industry Overview - The coal machinery industry is seeing increased concentration, with leading state-owned enterprises poised to benefit from this trend [1] - The demand for coal machinery is driven by factors such as replacement needs, automation, and the trend of consolidating smaller mines into larger operations [1]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [5]. Core Insights - The analog chip market is entering an upcycle, with Analog Devices Inc. (ADI) planning a price increase of approximately 15% across its product line starting February 1, 2026, driven by inflationary pressures in raw materials, labor, energy, and logistics [1]. - The company achieved a revenue of 1.531 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 80.47%, with net profit reaching 126 million yuan, an increase of 2.25 billion yuan year-on-year [2]. - The company is positioned to benefit from the accelerated domestic substitution process in the analog chip sector, leveraging its competitive pricing [1]. Summary by Relevant Sections Revenue and Profitability - For the first three quarters of 2025, the company's revenue from signal chain products was 1.012 billion yuan, up 42.64% year-on-year, while revenue from power management chips surged to 517 million yuan, reflecting a growth of 274.08% [2]. - The company forecasts a net profit of 186 million yuan for 2025, revised up by 26%, while the 2026 net profit estimate is adjusted down to 314 million yuan, a decrease of 23% [3]. Market Position and Product Development - The company is expanding its product offerings in the signal chain and power management sectors, targeting key markets such as industrial, automotive, communication, and consumer electronics [1]. - The company has seen significant growth in its optical module business, with several high-value analog chip products achieving large-scale shipments [2]. Financial Projections - The company is expected to generate revenues of 2.166 billion yuan in 2025, with a projected growth rate of 77.57%, and net profits are anticipated to reach 314 million yuan in 2026 [4]. - The estimated earnings per share (EPS) for 2025 is projected at 1.35 yuan, with a price-to-earnings (P/E) ratio of 129 [4][11].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market [5]. Core Insights - The company is expected to achieve net profits of 90.5 billion, 95.1 billion, and 101.6 billion for the years 2025 to 2027, respectively, with corresponding price-to-earnings (PE) ratios of 20x, 19x, and 17x [5]. - The company is undergoing a comprehensive market-oriented reform in 2026, focusing on product, pricing, and channel strategies, which is anticipated to open up long-term growth opportunities [5]. - The adjustment of the product matrix by the company includes six major series, enhancing its product structure and pricing clarity, which is expected to stabilize and potentially increase sales [5][6]. Financial Data and Profit Forecast - The total revenue for 2025 is projected to be 183.2 billion, with a year-on-year growth rate of 5.2%, and net profit is expected to be 90.5 billion, reflecting a growth rate of 4.9% [7]. - The gross profit margin is expected to remain high at around 91.6% for the forecasted years [7]. - The return on equity (ROE) is projected to be 34.9%, 33.2%, and 32.1% for the years 2025 to 2027, indicating strong profitability [7]. Market Dynamics - The current price of the 500ml Flying Moutai is 1540 yuan, with expectations that the price will stabilize due to supply-demand adjustments through the company's new initiatives [6]. - The company anticipates a significant increase in sales during the upcoming Spring Festival, driven by improved price competitiveness and increased consumer access through its new platform [6].

Investment Rating - The investment rating for the company is "Buy-A" with a 12-month target price of 7.35 yuan, while the current stock price is 6.18 yuan [5]. Core Insights - The company has signed a strategic cooperation agreement with Jingtai Technology to develop AI+robotics high-throughput perovskite solar cell technology, aiming to enhance competitive advantages in photovoltaic products [1][2]. - The perovskite tandem technology is seen as a key direction for the future of the photovoltaic industry, with the company achieving a new breakthrough in conversion efficiency of 34.76% for its TOPCon-based perovskite tandem cells [3]. - The energy storage business is expected to turn profitable soon, with a projected shipment volume of 3.3 GWh in the first three quarters of 2025 and plans for significant growth in 2026 [4]. Summary by Sections Strategic Cooperation - The collaboration aims to create the world's first AI-driven, robot-executed, and data-feedback closed-loop manufacturing line for tandem solar cells, significantly improving research and development efficiency [2]. - The new experimental line is expected to achieve a throughput of 1000 cells per day, enhancing R&D efficiency by a factor of 100 [2]. Technological Advancements - The company has improved its TOPCon cell efficiency to 27.79% and plans to upgrade 40%-50% of its existing capacity by the end of 2025, with mainstream models exceeding 640W [3]. - The strategic partnership is crucial for consolidating the company's long-term technological advantages and capturing the next generation of technology leadership [3]. Energy Storage Business - The company is deepening its strategic layout in the new energy storage sector, with a focus on large-scale and commercial energy storage projects, achieving an international order ratio of approximately 80% [4]. - The energy storage business is anticipated to contribute stable profits starting in 2026, supported by a production capacity of 17 GWh for system integration and 5 GWh for cell self-supply [4]. Financial Projections - The company is projected to have net profits of -4.5 billion yuan in 2025, followed by 2.13 billion yuan in 2026 and 3.57 billion yuan in 2027, indicating a significant turnaround [9]. - The company is compared with peers like Longi Green Energy, JA Solar, and Trina Solar, highlighting its leading position in TOPCon technology and rapid growth in the energy storage sector [9].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook on its stock performance relative to the market benchmark [6][7]. Core Insights - The company achieved record monthly sales for both its brands, with total sales surpassing 200,000 units in 2025. The cumulative sales for January to December 2026 reached 209,600 units, reflecting a year-on-year increase of 84.06% [6][7]. - The company’s new vehicle cycle is expected to drive continued sales growth, with multiple new models set to launch in 2026 [6][7]. - The company’s gross margin turned positive in Q3, supported by the scale effect and new vehicle launches, with a projected revenue growth of 93.34% in 2025 [6][7]. Sales Performance - In December, the company sold 35,200 vehicles, marking a year-on-year increase of 114.56%, the highest monthly sales since 2020 [6][7]. - The brand "极狐" (Jihu) achieved annual sales exceeding 160,000 units, maintaining a doubling of sales for three consecutive years [6][7]. - The brand "享界" (Xiangjie) recorded its first monthly sales exceeding 10,000 units in December, solidifying its position as a leader in the luxury new energy vehicle segment [6][7]. New Model Launches - The company launched several new models in the latter half of 2025, including the "极狐T1" and "享界S9T," which contributed to a steady increase in monthly sales from August to December [6][7]. - The "极狐S3" and the first MPV from the brand are expected to launch in 2026, further enhancing the product lineup and sales potential [6][7]. Sales Network Expansion - The company is accelerating its sales network expansion, with the number of operational stores reaching 244 by the end of 2023, and plans to increase to 320 by the end of 2024 and 547 by the end of 2025 [7]. Financial Projections - Revenue projections for 2025-2027 are estimated at 280.57 billion, 583.93 billion, and 847.25 billion yuan, with respective year-on-year growth rates of 93.34%, 108.12%, and 45.09% [7][10]. - The net profit attributable to the parent company is projected to improve from a loss of 45.03 billion yuan in 2025 to a profit of 13.06 billion yuan in 2027 [7][10].

Investment Rating - The investment rating for the company is "Buy-A" with a 12-month target price of 71.95 CNY per share [4]. Core Insights - The report highlights that the company is entering a significant growth phase with multiple new products in the domestic market and the overseas market poised for key data readouts, particularly for the long-acting eye drug EYP-1901 [1][2][3]. Summary by Sections Overseas Market - EYP-1901, a long-acting eye drug, is expected to read out phase 3 clinical data for wet age-related macular degeneration (wAMD) by mid-2026, which could catalyze significant market potential [2][24]. - The competitive landscape for VEGF small molecule eye drugs is favorable, with EYP-1901 leading in development progress [2][30]. - EYP-1901 offers a differentiated advantage with a dosing frequency of once every six months, which is expected to significantly improve patient adherence compared to current treatments like Aflibercept, which requires dosing every two months [2][34]. Domestic Market - The company has several new products entering a rapid growth phase, including plant-derived recombinant albumin and long-acting factor VIII, which are expected to capture significant market share [3][21]. - The sales of Enasidenib and Bevacizumab are accelerating, indicating strong growth potential in the lung cancer and other oncology markets [3][21]. - Revenue projections for the company are optimistic, with expected revenues of 3.55 billion CNY, 4.46 billion CNY, and 5.48 billion CNY for 2025, 2026, and 2027 respectively, alongside net profits of 409 million CNY, 704 million CNY, and 896 million CNY for the same years [3][8]. Financial Forecast - The company is projected to achieve a revenue growth rate of approximately 15.9% year-on-year for the first three quarters of 2025, driven by the launch of multiple new drugs [17][21]. - The earnings per share (EPS) are expected to increase from 0.97 CNY in 2025 to 2.13 CNY in 2027, reflecting a strong growth trajectory [8][21].

Investment Rating - The report assigns a "Buy" rating for the company Biocytogen (688796) [2]. Core Insights - Biocytogen is a rapidly growing biotechnology platform that has successfully completed dual listings in both A and H shares. The company operates two main platforms: the RenMice platform for antibody drug development and the BioMice platform for preclinical products and services. The company has a history of significant revenue growth and is expected to turn profitable in 2024 [3][17]. - The RenMice platform is positioned to contribute high growth potential, with a focus on developing fully human antibodies. The company has initiated the "Thousand Mice, Ten Thousand Antibodies" program, which aims to create a vast library of antibody sequences targeting numerous druggable targets [4][15]. - The BioMice platform is expected to provide stable cash flow, leveraging the company's expertise in model animals and pharmacological evaluation services. The company has developed over 4,300 genetically modified animals and has established a comprehensive pharmacological evaluation system [5][16]. Summary by Sections Company Overview - Biocytogen is an international biotechnology company focused on innovative drug development, with its headquarters in Beijing and branches in the US and Germany. The company has developed a significant library of over 1 million fully human antibody sequences and offers various preclinical services [3][17][20]. RenMice Platform - The RenMice platform is a leading technology for fully human antibody development, utilizing advanced gene editing techniques. The company has launched the "Thousand Mice, Ten Thousand Antibodies" initiative to develop antibodies against over 1,000 potential drug targets, resulting in a library of over 1 million antibody sequences [4][15][48]. BioMice Platform - The BioMice platform focuses on model animals and pharmacological evaluation, with a market size projected to reach approximately 4.44 billion USD globally by 2024. The company has developed over 4,300 genetically modified animals and has completed over 6,350 drug evaluations for approximately 950 partners [5][16][23]. Financial Projections - The company is expected to achieve revenues of 1.35 billion CNY, 1.80 billion CNY, and 2.32 billion CNY for the years 2025, 2026, and 2027, respectively. The net profit attributable to the parent company is projected to be 150 million CNY, 318 million CNY, and 507 million CNY for the same years [7][9][38]. Management and Governance - The company has a clear ownership structure with a stable controlling relationship. The management team possesses extensive experience in biomedical fields, contributing to the company's strategic direction and operational success [30][34].